Presentation Slides PDF – Click here
Biography:
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Alongside his clinical practice, his research focusses on large-scale streamlined trials. He has delivered trials in cardiovascular disease and was co-principal investigator of EMPA-KIDNEY which demonstrated the efficacy and safety of empagliflozin in people with CKD. He also led his trials unit delivery of the RECOVERY trial which was the largest trial of treatments for covid-19.